Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Immunocore Holdings and keeping the price target at $100.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors, including the impressive revenue growth of Immunocore Holdings’ KIMMTRAK in the first half of 2025. This growth has surpassed expectations and supports the company’s pipeline expansion, particularly in autoimmune programs. The company’s financial performance, highlighted by a 30% year-over-year increase in net product revenue for the second quarter of 2025, demonstrates the strong market uptake of KIMMTRAK across the U.S. and Europe.
Additionally, Immunocore is making significant progress in its clinical trials, with two Phase 3 trials for tebentafusp in earlier-stage diseases and advancements in its PRAME franchise. The company’s efforts in infectious diseases and autoimmune programs further bolster its growth prospects. With a robust cash position and a diverse clinical pipeline, Trucchio believes Immunocore is well-positioned for sustained growth, reinforcing his Buy rating and $100 price target.
In another report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $60.00 price target.